Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front pharmacol. 2022;13:868695.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–42.

CAS  PubMed  PubMed Central  Google Scholar 

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wildiers H, Armstrong A, Cuypere E, Dalenc F, Dirix L, Chan S, et al. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial. Clin Cancer Res. 2024;30(3):532–41.

Article  CAS  PubMed  Google Scholar 

Heater NK, Franco S, Shah A. Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates. Annals of Translational Medicine. 2023;11(11):399.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of <scp>DS</scp>-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmid P, Loi S, De La Cruz ML, Yerushalmi R, Im SA, Sonnenblick A, et al. 181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: a phase Ib/II study of multiple treatment (tx) combinations in pts with locally advance. ESMO Open. 2024;9:103203.

Article  Google Scholar 

Burke EE, Kodumudi K, Ramamoorthi G, Czerniecki BJ. Vaccine therapies for breast cancer. Surg Oncol Clin N Am. 2019;28(3):353–67.

Article  PubMed  Google Scholar 

Mohebtash M, Tsang K-Y, Madan RA, Huen N-Y, Poole DJ, Jochems C, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2011;17(22):7164–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28.

Article  PubMed  PubMed Central  Google Scholar 

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21.

Article  CAS  PubMed  Google Scholar 

Núñez Abad M, Calabuig-Fariñas S, Lobo De Mena M, Torres-Martínez S, García González C, García García JÁ, et al. Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer. Cancers. 2022;14(2):307.

Article  PubMed  PubMed Central  Google Scholar 

Erber R, Hartmann A. Understanding PD-L1 testing in breast cancer: a practical approach. Breast Care. 2020;15(5):481–90.

Article  PubMed  PubMed Central  Google Scholar 

Scott ML, Ratcliffe MJ, Sharpe A, Barker C, Scorer P, Rebelatto M, Al-Masri H, Walker J. Concordance of tumor cell (TC) and immune cell (IC) staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 IHC tests in NSCLC patient samples. J Clin Oncol. 2017;35(15_suppl):e14503–e14503. https://doi.org/10.1200/JCO.2017.35.15_suppl.e14503.

Article  Google Scholar 

Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217–26.

Article  CAS  PubMed  Google Scholar 

Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–13.

Article  CAS  PubMed  Google Scholar 

Pellegrino B, Musolino A, Llop-Guevara A, Serra V, De Silva P, Hlavata Z, et al. Homologous recombination repair deficiency and the immune response in breast cancer: a literature review. Transl Oncol. 2020;13(2):410–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karn T, Denkert C, Weber KE, Holtrich U, Hanusch C, Sinn BV, et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol. 2020;31(9):1216–22.

Article  CAS  PubMed  Google Scholar 

Aggarwal C, Ben-Shachar R, Gao Y, Hyun SW, Rivers Z, Epstein C, et al. Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Netw Open. 2023;6(5):e2311181.

Article  PubMed  PubMed Central  Google Scholar 

Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929–38.

Article  CAS  PubMed  Google Scholar 

Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, et al. Immuno-oncology-101: overview of major concepts and translational perspectives. Semin Cancer Biol. 2018;52:1–11.

Article  CAS  PubMed  Google Scholar 

Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279–88.

Article  CAS  PubMed  Google Scholar 

Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, et al. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. npj Breast Cancer. 2022. https://doi.org/10.1038/s41523-021-00362-1.

Article  PubMed  PubMed Central  Google Scholar 

Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504–15.

Article  CAS  PubMed  Google Scholar 

Yin Q, Liuyun W, Han L, Zheng X, Tong R, Li L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023. https://doi.org/10.3389/fimmu.2023.1167975.

Article  PubMed  PubMed Central  Google Scholar 

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–126.

Article  CAS  PubMed  Google Scholar 

Bai R, Chen N, Li L, Du N, Bai L, Lv Z, et al. Mechanisms of cancer resistance to immunotherapy. Front oncol. 2020;10:1290.

Article  PubMed  PubMed Central  Google Scholar 

Said SS, Ibrahim WN. Cancer resistance to immunotherapy: comprehensive insights with future perspectives. Pharmaceutics. 2023;15(4):1143.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US Incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055.

Article  PubMed  PubMed Central  Google Scholar